Text Size
171 studies found for:    Amyloidosis

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Burden of Illness Study In Patients With Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP) orTransthyretin Cardiomyopathy (TTR-CM) And Caregivers
Conditions: Transthyretin Familial Amyloidosis Polyneuropathy (TTR-FAP);   Transthyretin Cardiomyopathy (TTR-CM);   Familial Amyloid Cardiomyopathy;   Senile Systemic Amyloidosis (SSA)
Intervention: Other: No drug
2 Recruiting A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis
Conditions: Amyloidosis;   Systemic Light-Chain Amyloidosis
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone
3 Recruiting Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy
Conditions: Cardiac Amyloidosis;   Amyloidosis in Transthyretin (TTR);   Hypertrophic Cardiomyopathy (HCM)
Intervention:
4 Recruiting The Effect of Diflunisal on Familial Transthyretin Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Diflunisal
5 Completed The Effect of Diflunisal on Familial Amyloidosis
Conditions: Familial Amyloid Polyneuropathy;   Familial Amyloidosis
Interventions: Drug: diflunisal;   Other: placebo
6 Recruiting Safety and Effect of Doxycycline in Patients With Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Doxycycline
7 Recruiting Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: Bortezomib (Velcade) and Dexamethasone
8 Recruiting Institutional Registry of Amyloidosis
Condition: Amyloidosis
Intervention:
9 Unknown † Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Condition: Amyloidosis
Intervention: Drug: Lenalidomide, Dexamethasone and Cyclophosphamide
10 Withdrawn Mixed Chimeric Transplantation for Primary Amyloidosis
Condition: Amyloidosis
Intervention: Procedure: autologous followed by nonmyeloablative allogeneic transplant
11 Completed Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis
Condition: Amyloidosis
Intervention: Drug: melphalan, thalidomide and dexamethasone
12 Recruiting Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
Condition: AL Amyloidosis
Interventions: Drug: Bendamustine;   Drug: Dexamethasone
13 Completed Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis
Condition: Amyloidosis
Interventions: Drug: cyclophosphamide;   Drug: lenalidomide;   Drug: dexamethasone
14 Unknown † Study of Systemic Amyloidosis Presentation and Prognosis
Condition: Amyloidosis
Intervention:
15 Not yet recruiting A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
Condition: Amyloidosis
Interventions: Drug: GSK2398852;   Drug: GSK2315698
16 Recruiting Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis
Condition: Amyloidosis
Interventions: Drug: KIACTA (eprodisate disodium);   Drug: Placebo
17 Recruiting Long-term Outcomes of Patients With Primary Amyloidosis After Stem Cell Transplantation
Condition: Amyloidosis
Intervention:
18 Recruiting Phase I, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Condition: Primary Amyloidosis
Intervention: Drug: NEOD001
19 Completed Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis
Condition: Amyloidosis
Interventions: Drug: Lenalidomide;   Drug: Melphalan;   Drug: Dexamethasone
20 Completed Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Conditions: Secondary (AA) Amyloidosis;   Rheumatoid Arthritis;   Nephrotic Syndrome;   Familial Mediterranean Syndrome;   Kidney Diseases;   Gastrointestinal Diseases
Intervention: Drug: NC-503 (Anti-amyloidotic (AA) Agent)
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years